Most stock quote data provided by BATS. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. Based on our forecasts, a long-term increase is expected, the "ABBV" stock price prognosis for 2028-02-23 is 287.522 USD. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. Below, I will outline how I see AbbVie putting the Humira LOE firmly behind it, and driving the high single digit percentage annual growth management has promised. AbbVie's free cash flow yield is 10.5% compared to 4.3% for Johnson & Johnson . MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. AbbVie declared a quarterly dividend on Thursday, February 16th. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. This indicates that the company will be able to sustain or increase its dividend. The most recent increase was . 16 analysts have issued 12-month price targets for AbbVie's shares. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. It . psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. Receive ABBV Stock News and Ratings via Email. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. Please. The official website for the company is www.abbvie.com. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! PEG Ratios above 1 indicate that a company could be overvalued. Since then, however, the stock price has fallen 18% to. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. AbbVie's stock is owned by many different institutional and retail investors. Please disable your ad-blocker and refresh. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. (AbbVie data). Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Currently, the company has a "stable" rating, but that must be maintained or investors will perceive the company as unsafe to invest in and that will drag the share price down rapidly. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. You should do your own research and never invest money you cannot afford to lose. CNN Sans & 2016 Cable News Network. . View ABBV analyst ratings or view top-rated stocks. Finally, AbbVie was able to raise its financial . In-depth profiles and analysis for 20,000 public companies. AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB 164.71 0.00 0.00%. Only you can design whether Abbvie stock is the right investment for you. Shares are consolidating with a buy. Abbvies first quarter 2022 financial results for the quarter ended 31 March revealed that diluted earnings per share (EPS) increased to $2.51 on a generally accepted accounting principles (GAAP) basis, up from $1.99 a year earlier. AbbVie stock is one of the most well-known pharmaceutical companies. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. AbbVie Inc. is a US-based biopharma company with global operations. The firm earned $15.12 billion during the quarter, compared to the consensus estimate of $15.30 billion. I write about Biotech, Pharma and Healthcare stocks and share investment tips. View institutional ownership trends. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. AbbVie probably does not want to be recognized as simply an immunology giant however, it wants to be substantially more diversified and like all major Pharma's it has a strong long-term focus on oncology. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. I wrote this article myself, and it expresses my own opinions. Forecast . I have no business relationship with any company whose stock is mentioned in this article. [email protected] That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. The company didn't offer a . Our first quarter results highlight the diversity of our portfolio and include compelling performance from key growth drivers Skyrizi, Rinvoq, Aesthetics and Neuroscience. All rights reserved. The first is Epcoritamab, a CD3xCD20 bispecific for B-cell malignancies, including DLBCL and follicular lymphoma, which AbbVie expects will be approved this year. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. Gene therapies have been a long time coming, having first been popularized in the early noughties. When I began this post it was in my mind to give AbbVie stock a "Hold" rating owing to an underwhelming - on some levels - set of Q2'22 earnings, some concerns around high revenue generating products such as Imbruvica, Juvederm, and Restasis, the disappearance of the Women's Health division, the imminent LOE for Humira and the high levels of debt. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. Only 0.08% of the stock of AbbVie is held by insiders. Projections are based on making fundamental and technical studies of the ABBV stock price performance. A AbbVie Inc. (NYSE:ABBV) insider lowered their holding by 87% earlier this year, These 2 Dividend Stocks Could Be a Great Addition to Your Income Portfolio, AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says, AbbVie (NYSE:ABBV) Receives New Coverage from Analysts at Guggenheim, AbbVie to Present at the Cowen 43rd Annual Health Care Conference, AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults with Moderate to Severe Crohn's Disease, AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO), 3 Stocks to Buy Right Now That Are Cash Cows, The painfully high price of Humira is patently wrong, AbbVie Inc. (NYSE:ABBV) SVP Sells $4,310,832.64 in Stock, StockNews.com Upgrades AbbVie (NYSE:ABBV) to "Strong-Buy", AbbVie Inc. (NYSE:ABBV) Director Sells $1,505,000.00 in Stock, Azita Saleki-Gerhardt Sells 25,000 Shares of AbbVie Inc. (NYSE:ABBV) Stock, AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need, view top-rated stocks among Wall Street analysts, 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. Nevertheless, after applying the discount factor, I calculate a share price target of $151 based on DCF analysis and a slightly higher figure of $168 based on EBITDA analysis. I believe AbbVie is likely 15 - 20% undervalued at current price. Read our dividend analysis for ABBV. As such, forecasting stock prices is more of an art than a science. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. How do I arrive at my share price target? Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. This means that . Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. Bhd., AbbVie Sp. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. All Rights Reserved. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. AbbVie passed that onto its 2022 guidance. And it couldnt be more wrong! All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. In my opinion, based on the current portfolio, AbbVie shares look undervalued below $160, but the upside above that price is limited, unless management is able to commercialize more products between now and the end of the decade, in order to achieve what looks like a very ambitious goal in driving high-single-digit revenue growth in the second half of this decade. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. Multidrug Resistant Bacteria Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2030) Published: March 2, 2023 at 2:55 a.m. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.79%. AbbVie CEO Gonzalez told the audience at the JPM Healthcare conference that: We now have a little over 90% access for next year for Humira at parity. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). AbbVie has been increasing its dividend for 51 years. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. View which stocks are hot on social media with MarketBeat's trending stocks report. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. (my tables and forecasting). AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year.